Showing 2981-2990 of 4166 results for "".
- Phase 1/2a Results of Lineage Cell's Retinal Pigment Epithelium Cell Transplant Therapy to Be Featured at ARVO Annual Meetinghttps://modernod.com/news/phase-12a-results-of-lineage-cells-retinal-pigment-epithelium-cell-transplant-therapy-to-be-featured-at-arvo-annual-meeting/2481451/Lineage Cell Therapeutics announced that results from imaging analyses of structural changes in addition to visual data from a phase 1/2a clinical study of RG6501 (OpRegen), will be presented at the 2023 Association for Research in Vision and Ophthalmology Annual Meeting in New Orleans.
- Kiora Pharmaceuticals Doses First Patient in ABACUS Phase 1b Study Evaluating KIO-301 for Retinitis Pigmentosahttps://modernod.com/news/kiora-pharmaceuticals-doses-first-patient-in-abacus-phase-1b-study-evaluating-kio-301-for-retinitis-pigmentosa/2481248/Kiora Pharmaceuticals announced the dosing of the first patient in a first-in-human open-label clinical trial for KIO-301, intended to restore vision loss in patients with retinitis pigmentosa (RP). "We are thrilled the first patient has been treated and I'm very enc
- Lumata Health Raises $4 Million in Series A Funding to Scale its Human-Led, Intelligent Eye Care Management Platformhttps://modernod.com/news/lumata-health-raises-4-million-in-series-a-funding-to-scale-its-human-led-intelligent-eye-care-management-platform/2481201/Lumata Health announces $4 million in new venture funding to scale its impact throughout the United States. Lumata Health currently serves thousands of patients suffering from vision-threatening chronic eye conditions through partnerships with ophthalmology clinics and h
- Nanoscope Announces Completion of Enrollment in STARLIGHT Phase 2 Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Diseasehttps://modernod.com/news/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease/2481089/Nanoscope Therapeutics announced full enrollment of its phase 2 clinical trial of MCO-010, an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic monotherapy to restore vision in blind patients, for Stargardt disease. Six-month data from the phase 2 STARLIGHT trial are exp
- New Study Shows Intraocular Lens Centration and Stability May Be Improved When Zepto Capsulotomy Platform is Used with Purkinje Reflectionshttps://modernod.com/news/new-study-shows-intraocular-lens-centration-and-stability-may-be-improved-when-zepto-capsulotomy-platform-is-used-with-purkinje-reflections/2480912/Centricity Vision announced the publication of a clinical study describing how to use Purkinje reflections at patient fixation for capsulotomy centration and 360-degree capsular overlap with the Zepto platform to help achieve improved visual outcomes. Published in the Journal
- NIH: Gene Therapy for Rare Eye Disease Safe But Lacks Efficacy in Early Trialhttps://modernod.com/news/nih-gene-therapy-for-rare-eye-disease-safe-but-lacks-efficacy-in-early-trial/2480896/A 28-patient phase 1 gene therapy clinical trial for the degenerative retinal disease Leber hereditary optic neuropathy (LHON) found no significant safety concerns; however, treatment failed to improve or slow vision loss, with even the highest dose. LHON affects the optic nerve, which carries vi
- Eyevensys Recaps Highlights from Investigator Meeting and Presentations at ARVOhttps://modernod.com/news/eyevensys-recaps-highlights-from-investigator-meeting-and-presentations-at-arvo/2480854/Eyevensys provided highlights from the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Conference in Denver, Colorado. In addition to its participation in the event, Eyevensys also held a successful meeting with principal investigators involved in its clinical trials
- Opthea Data for OPT-302 in Combination With Ranibizumab for PCV Presented at ARVOhttps://modernod.com/news/opthea-data-for-opt-302-in-combination-with-ranibizumab-for-pcv-presented-at-arvo-2022/2480848/Opthea announced that clinical data was presented at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting. The presentation, titled “Efficacy and Safety of OPT-302 in combination with Ranibizumab for Polypoidal Choroidal Vasculopathy,” was held
- Study Shows Reduction in Postoperative Halos in Patients Treated With Tearscience Lipiflow Treatment Prior to Bilaterial Cataract Surgeryhttps://modernod.com/news/study-shows-reduction-in-postoperative-halosin-patients-treated-with-tearscience-lipiflow-treatment-prior-to-bilaterial-cataract-surgery/2479413/Johnson & Johnson Vision revealed new comparative clinical study findings evaluating TearScience LipiFlow treatment in cataract surgery. The data concluded that treating patients with TearScience LipiFlow prior to cataract surgery significantly reduced patient-reports of halos compared to con
- Eyenovia Highlights Recent Progress in Three Phase 3 Programs, NDA Review Progress, and Licensing Agreementshttps://modernod.com/news/eyenovia-highlights-recent-progress-in-three-phase-3-programs-nda-review-progress-and-licensing-agreements/2479294/Eyenovia provided a corporate update on its pipeline with recent and upcoming milestones. Eyenovia previously announced initial topline data from its phase 3 VISION-1 clinical trial, which evaluated the company’s proprietary pilocarpine solution, administere